Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response

References

• LouisDNOhgakiHWiestlerODThe 2007 WHO classification of tumours of the central nervous systemActa Neuropathol200711429710917618441
   PubMed Web of Science ®Google Scholar
• DunnGPRinneMLWykoskyJEmerging insights into the molecular and cellular basis of glioblastomaGenes Dev201226875678422508724
   PubMed Web of Science ®Google Scholar
• DolecekTAProppJMStroupNEKruchkoCCBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009Neuro Oncol201214Suppl 5v1v4923095881
   PubMed Web of Science ®Google Scholar
• TamberMSRutkaJTPediatric supratentorial high-grade gliomasNeurosurg Focus2003142e115727422
   PubMedGoogle Scholar
• FleuryAMenegozFGrosclaudePDescriptive epidemiology of cerebral gliomas in FranceCancer1997796119512029070498
   PubMed Web of Science ®Google Scholar
• BurnetNGJefferiesSJBensonRJHuntDPTreasureFPYears of life lost (YLL) from cancer is an important measure of population burden – and should be considered when allocating research fundsBr J Cancer200592224124515655548
   PubMed Web of Science ®Google Scholar
• ClaesAIdemaAJWesselingPDiffuse glioma growth: a guerilla warActa Neuropathol2007114544345817805551
   PubMed Web of Science ®Google Scholar
• StuppRMasonWPvan den BentMJRadiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J Med20053521098799615758009
   PubMed Web of Science ®Google Scholar
• StuppRHegiMEMasonWPEffects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialLancet Oncol200910545946619269895
   PubMed Web of Science ®Google Scholar
• HegiMEDiserensA-CGorliaTMGMT gene silencing and benefit from temozolomide in glioblastomaN Engl J Med200535210997100315758010
   PubMed Web of Science ®Google Scholar
• WellerMCloughesyTPerryJRWickWStandards of care for treatment of recurrent glioblastoma – are we there yet?Neuro Oncol201315142723136223
   PubMed Web of Science ®Google Scholar
• AntonKBaehringJMMayerTGlioblastoma multiforme: overview of current treatment and future perspectivesHematol Oncol Clin North Am201226482585322794286
   PubMed Web of Science ®Google Scholar
• ChaichanaKLZadnikPWeingartJDMultiple resections for patients with glioblastoma: prolonging survivalJ Neurosurg2013118481282023082884
   PubMed Web of Science ®Google Scholar
• WongEGautamSMalchowCLunMPanEBremSBevacizumab for recurrent glioblastoma multiforme: a meta-analysisJ Natl Compr Cancer Netw201294403407
   Web of Science ®Google Scholar
• SalmaggiAMilanesiISilvaniAProspective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary resultsJ Neurosurg2013118482182923350777
   PubMed Web of Science ®Google Scholar
• ChioccaEAAguilarLKBellSDPhase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant gliomaJ Clin Oncol201129273611361921844505
   PubMed Web of Science ®Google Scholar
• StuppRWongETKannerAANovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modalityEur J Cancer201248142192220222608262
   PubMed Web of Science ®Google Scholar
• KantoffPWHiganoCSShoreNDSipuleucel-T immunotherapy for castration-resistant prostate cancerN Engl J Med2012363541142220818862
   PubMed Web of Science ®Google Scholar
• SchwartzentruberDJLawsonDHRichardsJMgp100 peptide vaccine and interleukin-2 in patients with advanced melanomaN Engl J Med2011364222119212721631324
   PubMed Web of Science ®Google Scholar
• MarshJCGoldfarbJShafmanTDDiazAZCurrent status of immunotherapy and gene therapy for high-grade gliomasCancer Control2013201434823302906
   PubMed Web of Science ®Google Scholar
• XuXStockhammerFSchmittMCellular-based immunotherapies for patients with glioblastoma multiformeClin Dev Immunol2012201276421322474481
   PubMedGoogle Scholar
• HeimbergerABSampsonJHImmunotherapy coming of age: what will it take to make it standard of care for glioblastoma?Neuro Oncol201113131321149252
   PubMed Web of Science ®Google Scholar
• VauleonEAvrilTColletBMosserJQuillienVOverview of cellular immunotherapy for patients with glioblastomaClin Dev Immunol20102010 pii: 689171
   PubMedGoogle Scholar
• Van GoolSMaesWArdonHVerschuereTVan CauterSDe VleeschouwerSDendritic cell therapy of high-grade gliomasBrain Pathol200919469471219744041
   PubMed Web of Science ®Google Scholar
• De VleeschouwerSRappMSorgRVDendritic cell vaccination in patients with malignant gliomas: current status and future directionsNeurosurgery200659598899917143233
   PubMed Web of Science ®Google Scholar
• De VleeschouwerSVan GoolSWVan CalenberghFImmunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cellsChilds Nerv Syst200521171815452731
   PubMed Web of Science ®Google Scholar
• AguilarLKArvizuMAguilar-CordovaEChioccaEAThe spectrum of vaccine therapies for patients with glioblastoma multiformeCurr Treat Options Oncol201213443745022903697
   PubMed Web of Science ®Google Scholar
• ThomasAAErnstoffMSFadulCEImmunotherapy for the treatment of glioblastomaCancer J2013181596822290259
   PubMed Web of Science ®Google Scholar
• KimWLiauLMDendritic cell vaccines for brain tumorsNeurosurg Clin N Am201121113915719944973
   PubMed Web of Science ®Google Scholar
• SampsonJHHeimbergerABArcherGEImmunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastomaJ Clin Oncol201028314722472920921459
   PubMed Web of Science ®Google Scholar
• BanchereauJBriereFCauxCImmunobiology of dendritic cellsAnnu Rev Immunol20001876781110837075
   PubMed Web of Science ®Google Scholar
• YamanakaRAbeTYajimaNVaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trialBr J Cancer20038971172117914520441
   PubMed Web of Science ®Google Scholar
• WheelerCJBlackKLLiuGThymic CD8+ T cell production strongly influences tumor antigen recognition and age-dependent glioma mortalityJ Immunol200317194927493314568975
   PubMed Web of Science ®Google Scholar
• YuJSLiuGYingHYongWHBlackKLWheelerCJVaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in Patients with malignant gliomaCancer Res200464144973497915256471
   PubMed Web of Science ®Google Scholar
• De VleeschouwerSVan CalenberghFDemaerelPTransient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case reportJ Neurosurg20041005 Suppl Pediatrics49249715287461
   PubMed Web of Science ®Google Scholar
• RutkowskiSDe VleeschouwerSKaempgenESurgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility studyBr J Cancer20049191656166215477864
   PubMed Web of Science ®Google Scholar
• YamanakaRHommaJYajimaNClinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trialClin Dev Immunol2005111141604167
   Google Scholar
• WheelerCJBlackKLLiuGVaccination elicits correlated immune and clinical responses in glioblastoma multiforme patientsCancer Res200868145955596418632651
   PubMed Web of Science ®Google Scholar
• De VleeschouwerSFieuwsSRutkowskiSPostoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiformeClin Cancer Res200814103098310418483377
   PubMed Web of Science ®Google Scholar
• PrinsRMCloughesyTFLiauLMCytomegalovirus immunity after vaccination with autologous glioblastoma lysateN Engl J Med2008359553954118669440
   PubMed Web of Science ®Google Scholar
• ArdonHVan GoolSLopesISIntegration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot studyJ Neurooncol201099226127220146084
   PubMed Web of Science ®Google Scholar
• ArdonHDe VleeschouwerSVan CalenberghFAdjuvant dendritic cell-based tumour vaccination for children with malignant brain tumoursPediatr Blood Cancer201054451952519852061
   PubMed Web of Science ®Google Scholar
• FadulCEFisherJLHamptonTHImmune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapyJ Immunother201134438238921499132
   PubMed Web of Science ®Google Scholar
• ElensIDe VleeschouwerSPauwelsFVan GoolSResection and Immunotherapy for Recurrent Grade III GliomaISRN Immunol2012201219
   Google Scholar
• ArdonHVan GoolSWVerschuereTIntegration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trialCancer Immunol Immunother201261112033204422527250
   PubMed Web of Science ®Google Scholar
• De VleeschouwerSArdonHVan CalenberghFStratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccinationCancer Immunol Immunother201261112105211222565485
   PubMed Web of Science ®Google Scholar
• PellegattaSEoliMFrigerioSThe natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysatesOncoimmunology201323e2340123802079
   PubMed Web of Science ®Google Scholar
• LaskyJLPanosyanEHPlantAAutologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomasAnticancer Res20133352047205623645755
   PubMed Web of Science ®Google Scholar
• LiauLMBlackKLMartinNATreatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case reportNeurosurg Focus200096e816817691
   PubMedGoogle Scholar
• YuJSWheelerCJZeltzerPMVaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltrationCancer Res200161384284711221866
   PubMed Web of Science ®Google Scholar
• LiauLMPrinsRMKiertscherSMDendritic cell vaccination in glioblastoma patients induces systemic and intracranial t-cell responses modulated by the local central nervous system tumor microenvironmentClin Cancer Res200511155515552516061868
   PubMed Web of Science ®Google Scholar
• SampsonJHArcherGEMitchellDAAn epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiformeMol Cancer Ther20108102773277919825799
   PubMed Web of Science ®Google Scholar
• OkadaHKalinskiPUedaRInduction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant gliomaJ Clin Oncol201129333033621149657
   PubMed Web of Science ®Google Scholar
• IwamiKShimatoSOhnoMPeptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor α2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 alleleCytotherapy201214673374222424217
   PubMed Web of Science ®Google Scholar
• AkiyamaYOshitaCKumeAα-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trialBMC Cancer201212162323270484
   PubMed Web of Science ®Google Scholar
• PhuphanichSWheelerCJRudnickJDPhase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastomaCancer Immunol Immunother201362112513522847020
   PubMed Web of Science ®Google Scholar
• CarusoDAOrmeLMNealeAMResults of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancerNeuro Oncol20046323624615279716
   PubMed Web of Science ®Google Scholar
• Vik-MoEONyakasMMikkelsenBVTherapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastomaCancer Immunol Immunother20136291499150923817721
   PubMed Web of Science ®Google Scholar
• WalkerDGLahertyRTomlinsonFHChuahTSchmidtCResults of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapyJ Clin Neurosci200815211412118083572
   PubMed Web of Science ®Google Scholar
• ChangC-NHuangY-CYangD-MA phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant gliomaJ Clin Neurosci20111881048105421715171
   PubMed Web of Science ®Google Scholar
• JieXHuaLJiangWFengFFengGHuaZClinical application of a dendritic cell vaccine raised against heat-shocked glioblastomaCell Biochem Biophys2012621919921909820
   PubMed Web of Science ®Google Scholar
• KikuchiTAkasakiYIrieMHommaSAbeTOhnoTResults of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cellsCancer Immunol Immunother200150733734411676393
   PubMed Web of Science ®Google Scholar
• KikuchiTAkasakiYAbeTVaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12Immunotherapy2004276452459
   PubMed Web of Science ®Google Scholar
• OkadaHLiebermanFSWalterKAAutologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomasJ Transl Med200756718093335
   PubMed Web of Science ®Google Scholar
• BehinAHoang-XuanKCarpentierAFDelattreJ-YPrimary brain tumours in adultsLancet201237998301984199622510398
   PubMed Web of Science ®Google Scholar
• LeeYScheckACCloughesyTFGene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger ageBMC Med Genomics200815218940004
   PubMed Web of Science ®Google Scholar
• FagnoniFFVescoviniRPasseriGShortage of circulating naive CD8(+) T cells provides new insights on immunodeficiency in agingBlood20009592860286810779432
   PubMed Web of Science ®Google Scholar
• MirimanoffR-OGorliaTMasonWRadiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trialJ Clin Oncol200624162563256916735709
   PubMed Web of Science ®Google Scholar
• GirndtMSesterUHaraldKHüngerFKöhlerHGlucocorticoids inhibit activation-dependent expression of costimulatory molecule B7-1 in human monocytesTransplantation19986633703759721807
   PubMed Web of Science ®Google Scholar
• BrennerAVLinetMSFineHAHistory of allergies and autoimmune diseases and risk of brain tumors in adultsInt J Cancer200299225225911979441
   PubMed Web of Science ®Google Scholar
• DixARBrooksWHRoszmanTLMorfordLAImmune defects observed in patients with primary malignant brain tumorsJ Neuroimmunol19991001–221623210695732
   PubMed Web of Science ®Google Scholar
• RodriguesJCGonzalezGCZhangLNormal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like propertiesNeuro Oncol201012435136520308313
   PubMed Web of Science ®Google Scholar
• RaychaudhuriBRaymanPIrelandJMyeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastomaNeuro Oncol201113659159921636707
   PubMed Web of Science ®Google Scholar
• SiddiquiMRistowKMarkovicSNAbsolute lymphocyte count predicts overall survival in follicular lymphomasBr J Haematol2006134659660116889618
   PubMed Web of Science ®Google Scholar
• EgeHGertzMAMarkovicSNPrediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective studyBr J Haematol2008141679279818410454
   PubMed Web of Science ®Google Scholar
• LissoniPBrivioFFumagalliLEfficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumorsInt J Biol Markers200419213514015255546
   PubMed Web of Science ®Google Scholar
• RochetNKottschadeLGrotzTPorrataLMarkovicSThe prognostic role of the preoperative absolute lymphocyte count and absolute monocyte count in patients with resected advanced melanomaAm J Clin Oncol Epub6142013
   Web of Science ®Google Scholar
• IwaseRShibaHHarukiKPost-operative lymphocyte count may predict the outcome of radical resection for galbladder carcinomaAnticancer Res20133383439344423898116
   PubMed Web of Science ®Google Scholar
• SchuenemanAJSugarEAUramJLow total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receiving a GM-CSF secreting pancreatic tumor vaccineAnn Surg Oncol201320Suppl 3S725S73024046118
   PubMed Web of Science ®Google Scholar
• GrossmanSAYeXLesserGImmunosuppression in patients with high-grade gliomas treated with radiation and temozolomideClin Cancer Res201117165473548021737504
   PubMed Web of Science ®Google Scholar
• SampsonJHAldapeKDArcherGEGreater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastomaNeuro Oncol201113332433321149254
   PubMed Web of Science ®Google Scholar
• DummerWNiethammerAGBaccalaRT cell homeostatic proliferation elicits effective antitumor autoimmunityJ Clin Invest2002110215715912122106
   PubMed Web of Science ®Google Scholar
• StummerWPichlmeierUMeinelTWiestlerODZanellaFReulenH-JFluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trialLancet Oncol20067539240116648043
   PubMed Web of Science ®Google Scholar
• StummerWReulenH-JMeinelTExtent of resection and survival in glioblastoma multiforme: identification of and adjustment for biasNeurosurgery200862356457618425006
   PubMed Web of Science ®Google Scholar
• SanaiNPolleyM-YMcDermottMWParsaATBergerMSAn extent of resection threshold for newly diagnosed glioblastomasJ Neurosurg201111513821417701
   PubMed Web of Science ®Google Scholar
• HuseJTPhillipsHSBrennanCWMolecular subclassification of diffuse gliomas: seeing order in the chaosGlia20115981190119921446051
   PubMed Web of Science ®Google Scholar
• BarajasRJrPhillipsJJParvataneniRRegional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR ImagingNeuro Oncol201214794295422711606
   PubMed Web of Science ®Google Scholar
• HodgesTRChoiBDBignerDDYanHSampsonJHIsocitrate dehydrogenase 1: what it means to the neurosurgeon: a reviewJ Neurosurg201311861176118023581583
   PubMed Web of Science ®Google Scholar
• YanHWilliams ParsonsDJinGIDH1 and IDH2 mutations in gliomasN Engl J Med2009360876577319228619
   PubMed Web of Science ®Google Scholar
• OhgakiHKleihuesPThe definition of primary and secondary glioblastomaClin Cancer Res201319476477223209033
   PubMed Web of Science ®Google Scholar
• ParsaATWaldronJSPannerALoss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in gliomaNat Med2007131848817159987
   PubMed Web of Science ®Google Scholar
• RutledgeWCKongJGaoJTumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional classClin Cancer Res201319184951496023864165
   PubMed Web of Science ®Google Scholar
• PhillipsHSKharbandaSChenRMolecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesisCancer Cell20069315717316530701
   PubMed Web of Science ®Google Scholar
• FreijeWACastro-VargasFEFangZGene expression profiling of gliomas strongly predicts survivalCancer Res2004646503651015374961
   PubMed Web of Science ®Google Scholar
• VerhaakRGHoadleyKAPurdomEIntegrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell20101719811020129251
   PubMed Web of Science ®Google Scholar
• SturmDWittHHovestadtVHotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastomaCancer Cell201222442543723079654
   PubMed Web of Science ®Google Scholar
• PrinsRMSotoHKonkankitVGene expression profile correlates with T cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapyClin Dev Immunol201117616031615
   Google Scholar
• NaeiniKMPopeWBCloughesyTFIdentifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance imagesNeuro Oncol201315562663423444259
   PubMed Web of Science ®Google Scholar
• DunnGPDunnIFCurryWTFocus on TILs: prognostic significance of tumor infiltrating lymphocytes in human gliomaCancer Immun200771217691714
   PubMedGoogle Scholar
• PalmaLDi LorenzoNGuidettiBLymphocytic infiltrates in primary glioblastomas and recidivous gliomasJ Neuroimmunol1978496854861
   Google Scholar
• RossiMJonesNCandyEThe mononuclear cell infiltrate compared with survival in high-grade astrocytomasActa Neuropathol19897821891932750489
   PubMed Web of Science ®Google Scholar
• SafdariHHochbergFHRichardsonEPPrognostic value of round cell (lymphocyte) infiltration in malignant gliomasSurg Neurol19852332212262983448
   PubMedGoogle Scholar
• YangITihanTHanSJCD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survivalJ Clin Neurosci201017111381138520727764
   PubMed Web of Science ®Google Scholar
• LohrJRatliffTHuppertzAEffector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-βClin cancer Res201117134296430821478334
   PubMed Web of Science ®Google Scholar
• SonabendAMRolleCELesniakMSThe role of regulatory T cells in malignant gliomaAnticancer Res2008282B1143115018505050
   PubMed Web of Science ®Google Scholar
• ArdonHVerbinnenBMaesWBeezTVan GoolSDe VleeschouwerSTechnical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccinationJ Immunol Methods20103521–216917319874827
   PubMed Web of Science ®Google Scholar
• HeimbergerABAbou-GhazalMReina-OrtizCIncidence and prognostic impact of FoxP3+ regulatory T cells in human gliomasClin Cancer Res200814165166517218698034
   PubMed Web of Science ®Google Scholar
• FecciPEMitchellDaWhitesidesJFIncreased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant gliomaCancer Res20066663294330216540683
   PubMed Web of Science ®Google Scholar
• El AndaloussiALesniakMSAn increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiformeNeuro Oncol20068323424316723631
   PubMed Web of Science ®Google Scholar
• JacobsJFMIdemaAJBolKFPrognostic significance and mechanism of Treg infiltration in human brain tumorsJ Neuroimmunol20102251–219519920537408
   PubMed Web of Science ®Google Scholar
• MaesWRosasGGVerbinnenBDC vaccination with anti-CD25 treatment leads to long-term immunity against experimental gliomaNeuro Oncol200911552954219336528
   PubMed Web of Science ®Google Scholar
• GrauerOMSutmullerRPMvan MarenWElimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma modelInt J Cancer200812281794180218076066
   PubMed Web of Science ®Google Scholar
• WainwrightDABalyasnikovaIVChangALIDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survivalClin Cancer Res201218226110612122932670
   PubMed Web of Science ®Google Scholar
• WainwrightDADeyMChangALesniakMSTargeting Tregs in malignant brain cancer: overcoming IDOFront Immunol2013411623720663
   PubMed Web of Science ®Google Scholar
• CharlesNAHollandECGilbertsonRGlassRKettenmannHThe brain tumor microenvironmentGlia20115981169118021446047
   PubMed Web of Science ®Google Scholar
• YangIHanSJKaurGCraneCParsaATThe role of microglia in central nervous system immunity and glioma immunologyJ Clin Neurosci201017161019926287
   PubMed Web of Science ®Google Scholar
• Da FonsecaACCBadieBMicroglia and macrophages in malignant gliomas: recent discoveries and implications for promising therapiesClin Dev Immunol2013201326412423864876
   PubMedGoogle Scholar
• KushchayevSVKushchayevaYSWienerPCBadieBPreulMCMonocyte-derived cells of the brain and malignant gliomas: the double face of JanusWorld Neurosurg Epub11232012
   Web of Science ®Google Scholar
• PyonteckSMAkkariLSchuhmacherAJCSF-1R inhibition alters macrophage polarization and blocks glioma progressionNat Med201319101264127224056773
   PubMed Web of Science ®Google Scholar
• FongBJinRWangXMonitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patientsPLoS One201274e3261422485134
   PubMed Web of Science ®Google Scholar
• VrabecMVan CauterSHimmelreichUMR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot studyNeuroradiology2011531072173121107549
   PubMed Web of Science ®Google Scholar
• FergusonPMSlocombeATilleyRDHermansIFUsing magnetic resonance imaging to evaluate dendritic cell-based vaccinationPLoS One201385e6531823734246
   PubMed Web of Science ®Google Scholar
• Engell-NoerregaardLHendelHWJohannesenHHAlslevLSvaneIMFDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanomaCancer Immunol Immunother2013621172522722450
   PubMed Web of Science ®Google Scholar
• ByrneHMDissecting cancer through mathematics: from the cell to the animal modelNat Rev Cancer201010322123020179714
   PubMed Web of Science ®Google Scholar
• BaldockALRockneRCBooneADFrom patient-specific mathematical neuro-oncology to precision medicineFront Oncol201336223565501
   PubMedGoogle Scholar
• GeorgiadiECDionysiouDDGrafNStamatakosGSTowards in silico oncology: adapting a four dimensional nephroblastoma treatment model to a clinical trial case based on multi-method sensitivity analysisComput Biol Med201242111064107823063290
   PubMed Web of Science ®Google Scholar
• StamatakosGSKolokotroniEDionysiouDIn silico oncology: exploiting clinical studies to clinically adapt and validate multiscale oncosimulatorsConf Proc IEEE Eng Med Biol Soc201320135545554924110993
   PubMedGoogle Scholar